Physician profile
Steve T Charles
NPI 1861495780
$5,799,924.94
in general payments reported to CMS, 2019-2025
29 companies · $579K in 2025
The $579K reported for 2025 was more than what 99% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1.2M · 2020: $1.0M · 2021: $842K · 2022: $825K · 2023: $849K · 2024: $469K · 2025: $579K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $1.4M · Consulting Fee: $411K · Travel and Lodging: $66K · Food and Beverage: $5,025 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $1,410,000.00 |
| Consulting Fee | $410,649.00 |
| Travel and Lodging | $65,742.70 |
| Food and Beverage | $5,024.83 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $4,407,277.67 | 2019-2025 | Unity, Constellation, Ngenuity |
| Alcon Research LLC | $1,177,139.15 | 2019-2025 | Luxor, Constellation, Ngenuity |
| Alcon Pharmaceuticals Ltd | $164,600.89 | 2019 | |
| Optovue, INC. | $35,000.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $8,142.45 | 2019-2022 | |
| Visionix USA, INC | $3,780.00 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $1,581.32 | 2019-2021 | |
| Alcon Grieshaber Ag | $412.50 | 2019 | |
| Genentech, INC. | $369.82 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $312.71 | 2020-2025 | Eylea, Eylea Hd |
| Apellis Pharmaceuticals, INC. | $303.77 | 2022-2025 | Syfovre |
| Genentech USA, INC. | $246.28 | 2019-2024 | Vabysmo |
| Mallinckrodt Hospital Products INC. | $160.26 | 2021-2023 | Acthar |
| Ocular Therapeutix, INC. | $118.05 | 2019-2024 | Dextenza |
| Allergan, INC. | $97.98 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| F. Hoffmann-La Roche Ag | $70.82 | 2019 | |
| Carl Zeiss Meditec, INC. | $69.76 | 2019 | |
| Boston Scientific Corporation | $44.38 | 2024 | Wavewriter Alpha Prime 16 |
| Abbvie INC. | $39.87 | 2023-2024 | Ozurdex |
| Regeneron Pharmaceuticals, INC. | $37.50 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $23.61 | 2025 | Visudyne, Xipere |
| Astellas Pharma US INC | $22.29 | 2024 | Izervay |
| Ani Pharmaceuticals, INC. | $21.40 | 2025 | Iluvien |
| Vyera Pharmaceuticals, LLC | $20.60 | 2019 | |
| Aerie Pharmaceuticals, INC. | $16.67 | 2019 | |
| Coherus Oncology, INC. | $15.19 | 2023 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Charles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.